[go: up one dir, main page]

EP1084261B1 - Vaccin antiviral recombinant de l'encephalite equine du venezuela - Google Patents

Vaccin antiviral recombinant de l'encephalite equine du venezuela Download PDF

Info

Publication number
EP1084261B1
EP1084261B1 EP99920967A EP99920967A EP1084261B1 EP 1084261 B1 EP1084261 B1 EP 1084261B1 EP 99920967 A EP99920967 A EP 99920967A EP 99920967 A EP99920967 A EP 99920967A EP 1084261 B1 EP1084261 B1 EP 1084261B1
Authority
EP
European Patent Office
Prior art keywords
virus
vaccine
vee
vector
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99920967A
Other languages
German (de)
English (en)
Other versions
EP1084261B8 (fr
EP1084261A1 (fr
Inventor
Alice Marie Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to DK99920967T priority Critical patent/DK1084261T3/da
Publication of EP1084261A1 publication Critical patent/EP1084261A1/fr
Application granted granted Critical
Publication of EP1084261B1 publication Critical patent/EP1084261B1/fr
Publication of EP1084261B8 publication Critical patent/EP1084261B8/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to a virus vaccine, specifically a vaccine to Venezuelan equine encephalomyelitis virus (VEE), to its preparation and pharmaceutically acceptable formulations and methods of prophylactic and therapeutic methods of treatment using said vaccine.
  • VEE Venezuelan equine encephalomyelitis virus
  • VEE virus is a mosquito-borne alphavirus which is an important cause of epidemic disease in humans and of epizootics in horses, donkeys and mules in certain parts of the world, in particular the South Americas.
  • VEE vaccine TC-83
  • TRD Trinidad donkey strain
  • TC-83 The existing VEE vaccine, TC-83, was initially produced by attenuation of the Trinidad donkey strain (TRD) of VEE by sequential passage in guinea pig heart cell cultures.
  • TRD Trinidad donkey strain
  • this vaccine is generally regarded as being inadequate for human vaccination. This is mainly due to the high incidence of side effects in vaccinees and the large proportion of vaccinees who fail to develop neutralising antibodies (Monath et al. 1992, Vaccine Research, 1 , 55-68).
  • a vaccinia-based vaccine against VEE has been constructed (Kinney et al. J. Gen. Virol. 1988, 69, 3005-3013).
  • 26S RNA encoding structural genes of VEE were inserted into the NYCBH strain of vaccinia.
  • the recombinant virus protected against sub-cutaneous challenge but had limited efficacy against aerosol challenge with VEE.
  • the virulent Trinidad donkey strain of VEE and the attenuated strain TC-83 have both been cloned and sequenced (R.M. Kinney et al. Virology (1989) 170 , 19-30) and the amino acid and nucleotide numbering system used in this reference will be used hereinafter. This work has revealed that there are a number of amino acid changes between TRD and TC-83. The majority (five) of these changes occur within the gene encoding the glycoprotein E2.
  • the first 25 amino acids of the E2 glycoprotein represents a protective epitope.
  • This region includes a single amino acid change (lys ⁇ asp) at amino acid 7 in the TC-83 construct as compared to the TRD strain.
  • a 25bp synthetic peptide based on the TRD sequence VE2pep01(TRD) protected more mice from TRD virus challenge than a corresponding TC-83 based peptide (A.R. Hunt et al., Virology, 1990, 179, 701-711). More precise mapping of this epitope has been carried out (A.R Hunt et al., Vaccine 1995, 13 , 3, 281-288).
  • the applicants have found ways of increasing the protectiveness of a vaccine and in particular a vaccinia-based vaccine.
  • the protectiveness of the vaccine may be increased either (a) by restoring the lysine residue at amino acid 7 of the E2 protein and/or (b) by modifying the promoter to increase expression of the protective construct.
  • the present invention provides a vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine comprising a vector which includes a sequence which encodes an attenuated form of said virus which is capable of producing a protective immune response, wherein the said sequence is such that the amino acid at position 7 in the E2 protein of VEE is lysine.
  • VEE Venezuelan Equine Encephalitis
  • the attenuated form of the VEE virus comprises a derivative or variant of the TC-83 construct or an immunogenic fragment thereof.
  • Other attenuated forms may be produced by the skilled person, for example using known techniques such as serial passage through another organism, or by recombinant DNA technology, for instance by inactivating genes associated with the replication or virulence of the virus.
  • the structural gene encoding the E2 glycoprotein or a fragment encoding at least the N-terminal 19 amino acids should be retained in order to retain immunogenicity of the construct.
  • Suitable fragments of the construct are those which include only some of the structural genes of the VEE peptide or which encode only part of the proteins encoded by said genes, provided the construct encodes sufficient antigenic determinants to ensure that it is capable of producing a protective immune response in a mammal to whom the construct is administered.
  • the term " variant" means that the construct is different to the original strain but that it encodes proteins and/or peptides which are the same or similar to those of wild-type VEE or immunogenic fragments thereof.
  • the changes in the nucleotide sequence may be silent in that they do not produce amino acid changes as compared to the original strain, or they may produce amino acid changes provided these do not alter function of the construct in terms of its ability to produce a protective immune response against VEE.
  • the construct may encode peptides or proteins which are 60% homologous to the wild-type proteins or peptides, suitably more than 80% homologous and preferably more than 90% homologous to the native protein sequence, and provided they produce antibodies which are cross-reactive with wild-type VEE, the protective effects of the construct may be retained.
  • Derivatives may have broadly similar structures but they are derived by manipulating the original constructs using recombinant DNA technology or chemical modification if appropriate.
  • the vector may contain the usual expression control functions such as promoters, enhancers and signal sequences, as well as a selection marker in order to allow detection of successful transformants.
  • the selection of these will depend upon the precise nature of the vector chosen and will be known to or readily determinable by a person skilled in the art.
  • the vector is a viral vector, for example a vector derived from vaccinia , adenovirus , or herpes simplex virus (HSV). It is suitably attenuated itself, to minimise any harmful effects associated with the virus on the host.
  • a viral vector for example a vector derived from vaccinia , adenovirus , or herpes simplex virus (HSV). It is suitably attenuated itself, to minimise any harmful effects associated with the virus on the host.
  • HSV herpes simplex virus
  • the vector is derived from vaccinia virus, as it has many properties which make it a suitable vector for vaccination, including its ability to efficiently stimulate humoral as well as cell-mediated immune responses.
  • Vaccinia has proven utility as a vaccine vehicle, following the Smallpox eradication programmes. It provides the potential for multi-valent vaccine construction and for oral administration. There are many attenuated strains currently available.
  • a suitable selection marker for inclusion in a vaccinia vector is the gpt marker gene.
  • a VEE vaccine was constructed using a WR strain of vaccinia in this work.
  • a more highly attenuated strain of vaccinia which would be more acceptable for use in humans is employed.
  • Such strains include Lister, which was used for wide scale vaccination against smallpox, NYVAC (Tartaglia et al , (1992). AIDS Research and Human Retroviruses 8 ,1445-1447) which contains specific genome deletions, or MVA (Mayr et al , (1975) Infection 3 , 6-14) which is also highly attenuated.
  • Vaccines based upon viral vectors are suitably formulated for parenteral administration as described above.
  • it is possible to formulate such vaccines for oral administration for example by incorporating the vector into a gut-colonising microorganism such as Salmonella and particularly S. typhimurium .
  • pTC-5A is a plasmid clone of cDNA encoding the structural genes of VEE virus strain TC-83 (Kinney et al. J. Gen. Virol. (1988) 69, 3005-30130).
  • the VEE cDNA is situated downstream of the vaccinia 7.5K promoter which drives expression of the VEE structural proteins when the plasmid is used to construct recombinant vaccinia viruses.
  • Modified 7.5K vaccinia promoters have previously been prepared (Davison & Moss, J. Mol. Biol. 210 , (1989) 749-769). It has been found that certain substitution mutations increase the strength of the promoter. By using synthetic promoters which include substitution mutations, the amount of VEE proteins produced from the recombinant virus was increased.
  • a vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus comprising a vaccinia virus vector which encodes an attenuated form of the VEE virus or a variant or fragment thereof which is capable of producing a protective immune response against VEE virus, expression of the said attenuated VEE virus being under the control of a synthetic 7.5K vaccinia promoter which has been subject to mutation which increases the level of VEE virus protein production as compared to the wild-type 7.5K promoter.
  • substitution mutations within the 7.5Kd promoter can be effective. These may be illustrated by the following Table:
  • the vaccine may comprise the vector itself but it is suitably formulated as a pharmaceutical composition in combination with a pharmaceutically acceptable carrier or excipient. Such compositions form a further aspect of the invention.
  • the compositions may be in a form suitable for oral or parenteral application.
  • Suitable carriers are well known in the art and include solid and liquid diluents, for example, water, saline or aqueous ethanol.
  • the liquid carrier is suitably sterile and pyrogen free.
  • compositions may be in the form of liquids suitable for infusion or injection, or syrups, suspensions or solutions, as well as solid forms such as capsules, tablets, or reconstitutable powders.
  • Constructs for use in the vaccines of the invention may be prepared by various means as will be understood in the art, ranging from modification of available constructs such as the wild-type virus using recombinant DNA technology or by synthetic means.
  • Recombinant DNA techniques include site directed mutagenesis, optionally involving PCR amplification as illustrated hereinafter.
  • recombinant vaccinia virus was constructed which expressed the structural genes of VEE as produced by a modified form of TC-83. The ability of the recombinant virus to elicit protective immune responses against virulent VEE disease was investigated.
  • the vaccine further comprises a cytokine or an active fragment or variant thereof.
  • the cytokine may itself be incorporated into the vaccine formulation, or more suitably, the vector may include a coding sequence which means that the cytokine is co-expressed by the vector.
  • suitable cytokines include interleukin 2 (IL-2) and interleukin 6 (IL-6).
  • cytokine is interleukin 2 (IL-2), which may be expressed from for example a vaccinia virus recombinant.
  • IL-2 is known to be responsible for the clonal expansion of antigen-activated T cells (Smith, (1984) Reviews in Immunology 2 , 319-333).
  • antibody levels can be enhanced using other cytokines.
  • expression of IL-6 by vaccinia vectors has been shown to induce a high level of IgG 1 (Ruby et al , 1992 Vaccine Research 1 , (4), 347-356), and IL-5 and IL-6 induced mucosal IgA responses to co-expressed influenza HA (Ramsay et al , (1994) Reproduction, Fertility and Development 6 , 389-392).
  • the vaccine of the present invention may be used to treat humans or animals. In particular it may be given to horses, as a veterinary vaccine, to prevent infection, or as a prophylactic or therapeutic vaccine for humans.
  • the vaccine of the invention may be incorporated into a multivalent vaccine in order to increase the benefit-to-risk ratio of vaccination.
  • the vaccines of the invention will produce an immune response in test animals including the production of antibodies.
  • These antibodies may be useful in passive vaccination programmes or in diagnosis of VEE virus disease.
  • the antibodies may form part of a kit as is conventional in the art.
  • pTC-5A a plasmid clone of cDNA encoding the structural genes of Venezuelan Equine Encephalitis virus, strain TC-83 was obtained from Dr. R, Kinney (Kinney et al, 1988, Journal of General Virology 69, 3005-3103). An Eco RI fragment containing the VEE cDNA was removed from pTC-5A and inserted into p1113 (Carroll, 1993, Ph.D.
  • Fig 1a which is a shuttle vector used for insertion of genes into the thymidine kinase locus of vaccinia with dominant selection of recombinant viruses based on resistance to mycophenolic acid (Falkner & Moss, 1988, Journal of Virology 62, 1849-1854).
  • the resulting plasmid, pAB100 was mixed with Lipofectin TM (Life Technologies) and used to transfect CV-1 cells infected with vaccinia virus, strain WR.
  • Recombinant viruses were designated WR100 and were subjected to three rounds of plaque-purification before preparation of stocks as described earlier (Mackett et al, 1985 DNA cloning (Volume II): a practical approach).
  • VEE E2 strain TC-83, situated in pTC-5A
  • pTC-5A The sequence of VEE E2, strain TC-83, situated in pTC-5A, was altered by one nucleotide substitution from T to G as position 1053 as compared to wild-type VEE TRD (Johnson et al. J. Gen. Virol. 1986, 67, 1951-1960). This resulted in an amino acid change from asparagine to lysine in the E2 protein when expressed from the vaccinia virus.
  • a cleavage site for restriction enzyme Nsi I occurs close to the site of the required nucleotide substitution.
  • a second Nsi I site is situated about 500bp upstream.
  • Oligonucleotide primers were used to amplify the DNA sequence between the Nsi I sites using the Polymerase Chain Reaction (PCR).
  • the downstream primer contained a nucleotide mismatch corresponding to the TRD sequence at this point.
  • the primer sequences are listed below.
  • the Nsi I cleavage sites and the position of the substituted nucleotide are underlined.
  • the PCR product was digested with Nsi I and used to replace the corresponding Nsi I fragment in pTC-5A, generating plasmid pAB101.
  • the nucleotide sequence of the relevant region in pAB101 was obtained to verify the sequence alteration.
  • pAB101 was then digested with Eco 1 to remove the VEE 26S RNA coding sequence which was transferred to the vaccinia shuttle vector plasmid p1113.
  • P1113 contains the selectable marker gpt which allows selection of recombinant vaccinia viruses.
  • the plasmid constructed by the addition of the VEE sequence to p1113 was designated pAB102.
  • a synthetic 7.5K vaccinia promoter was designed, based upon work by Davison and Moss (supra.). Complementary oligonucleotides were designed with 5' Bam HI and 3' Eco RI ends. The oligonucleotides were annealed and ligated into the plasmid pT7Blue (available from AMS Biotechnology (UK) Ltd). The plasmid clone was digested with Bam HI and Eco RI and the DNA fragment containing the synthetic promoter was isolated and cloned into the plasmid pAB102 which had been cut with the same enzymes.
  • plasmid pAB103 Figure 1 which contains the synthetic promoter upstream of the VEE 26S RNA coding sequence.
  • Vaccinia WR strain was transformed with PAB103 to produce the recombinant vaccinia virus WR103.
  • oligonucleotide sequence is given below. Substitutions in the 7.5K promoter sequence are given in bold type. Insertions are underlined. Oligonucleotide " tails" containing restriction enzyme cleavage sites are italicised.
  • Oligo 1 designated " 7.5KF2"
  • Oligo 2 designated " 7.5KR2"
  • the amount of VEE proteins produced by the recombinant virus WR103 was measured using enzyme linked immunoabsorbant assay (ELISA) .
  • VEE viral proteins were visualised by indirect immunofluorescence of infected CV-1 cells.
  • CV-1 monolayers 25cm 2
  • virus at a multiplicity of 2 p.f.u. per cell.
  • PBS phophate-buffered saline
  • cells were scraped into the growth media and washed once with phophate-buffered saline (PBS) containing 0.1% bovine serum albumin. Cells were spotted onto slides, air-dried and fixed in acetone. Binding of mouse polyclonal antiserum raised against VEE strain TC-80 (provided by Dr. A.D.T. Barrett, University of Texas) was detected with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Amersham International plc).
  • VEE viral protein expression was carried out using an enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • the supernatant was removed and stored at -70°C.
  • the cell lysate preparation was diluted 1/30 in bicarbonate buffer (Sigma), 100 l volumes were added to wells of a microtitre plate and the antigen was allowed to bind at 37°C for 1 hour. Lysates were replaced with 200 l/well of saline containing 10% formaldehyde. Plates were incubated at room temperature for 20 minutes, then washed 6 times with PBS containing 0.1% Tween (PBST). Mouse polyclonal anti-TC80 was serially diluted in blocking solution (0.5% dried milk/PBST), added to wells, and the plates were incubated for 1 hour at 37°C.
  • PBST PBS containing 0.1% Tween
  • mice Groups (10) of female 6-8 week old Balb/c mice were inoculated with PBS or with 10 8 p.f.u. of vaccinia viruses by intramuscular injection, or with 10 5 p.f.u. of TC-83 by sub-cutaneous injection. Serum was taken for measurement of immunoglobulins to VEE proteins.
  • mice were challenged with two different doses of virulent VEE strain TRD at 35 days after immunisation.
  • the survival rates after 14 days are presented in Table 2.
  • VEE virus-specific immunoglobulin in serum was measured by enzyme-linked immunoassay as follows. Wells of a microtitre plate were coated with purified TC-83 at 37°C for 1 hour. Serum was diluted serially in blocking solution and allowed to bind to antigen-coated wells overnight at 4°C. Plates were washed 3 times and incubated with horseradish peroxidase-conjugated anti-mouse immunoglobulin at 37°C for 1 hour. Plates were washed and incubated with TMB substrate for 20 minutes before measurement of colour development at A 450 .
  • mice responded to the vaccination by the detection of immunoglobulin to vaccinia virus in serum (data not shown).
  • Immunoassay to measure TC-83 antibody failed to detect anti-VEE IgG in WR100 samples.
  • WR103 samples contained a detectable level of anti-VEE antibody although this was substantially lower than the amount found in serum from mice vaccinated with TC-83 ( Figure 4).
  • Neutralising antibody was measured by a plaque reduction test. Serum (10 ⁇ l) was incubated with TC-83 (50 ⁇ l) and maintenance medium (140 ⁇ l) for 1 hour at room temperature. Maintenance medium (800 ⁇ l) was added and the suspension was used to infect confluent monolayers of BHK-21 cells grown in 6-well plates. Plates were incubated at 37°C for 3 days. A 50% reduction in the number of plaques per well, compared to control wells, was indicative of the presence of neutralising antibody.
  • Neutralising antibody to TC-83 was found in serum from mice vaccinated with TC-83 but was not detected in serum from mice vaccinated with WR100 or WR103 (data not shown). Although neutralising antibody is usually found in mice which are protected against VEE challenge, protection has previously been reported in the absence of detectable neutralising antibody (Kinney et al, 1988a, Journal of Virology 62, 4697-4702).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vaccin prophylactique ou thérapeutique destiné à protéger les mammifères, humains ou animaux, contre le virus de l'encéphalite équine du Venezuela (VEE). En particulier, le vaccin comprend un virus recombinant, tel qu'un virus vaccinal recombinant capable d'exprimer les gènes de structure du VEE sous forme atténuée, qui peut être modifié pour accroître l'effet protecteur du vaccin. Ceci est obtenu en modifiant la séquence de la souche VEE atténuée et/ou en la plaçant sous le contrôle d'un promoteur modifié qui accroît l'expression à partir du vecteur. L'invention concerne également des formulations du vaccin ainsi que des procédés de traitement utilisant ledit vaccin.

Claims (17)

  1. Vaccin destiné à l'immunisation thérapeutique ou prophylactique contre le virus de l'encéphalite équine du Venezuela (VEE), ledit vaccin comprenant un vecteur qui comprend une séquence qui code pour une forme atténuée dudit virus qui est capable de produire une réponse immunitaire protectrice, dans lequel ladite séquence comprend au moins les 19 acides aminés N-terminaux de la glycoprotéine E2 et dans lequel l'acide aminé en position 7 dans la protéine E2 du VEE est la lysine.
  2. Vaccin selon la revendication 1, dans lequel la forme atténuée dudit virus comprend un dérivé de la construction TC-83.
  3. Vaccin selon la revendication 2, dans lequel le vecteur comprend un vecteur viral.
  4. Vaccin selon la revendication 3, dans lequel le virus est choisi à partir d'un virus atténué.
  5. Vaccin selon la revendication 3 ou la revendication 4, dans lequel le virus est choisi parmi le virus de la vaccine, un adénovirus ou le HSV.
  6. Vaccin selon la revendication 5, qui comprend un virus de la vaccine atténué.
  7. Vaccin selon la revendication 6, dans lequel l'expression dudit virus VEE atténué est sous le contrôle d'un promoteur 7,5 K du virus de la vaccine qui a été soumis à une mutation qui fait augmenter le taux de production de la protéine du virus VEE comparé au promoteur 7,5 K de type sauvage.
  8. Vaccin selon la revendication 7, dans lequel ledit promoteur 7,5 K comprend une séquence choisie parmi :
    Figure 00230001
    ou
    Figure 00230002
  9. Vaccin selon l'une quelconque des revendications précédentes, qui comprend un vecteur qui inclut une séquence nucléotidique qui code pour un autre peptide immunogène, et est capable d'exprimer ladite séquence lorsqu'il est administré à un mammifère.
  10. Vaccin selon l'une quelconque des revendications précédentes, qui comprend en outre une cytokine ou un fragment actif ou un variant de celle-ci, ou un vecteur qui comprend une séquence nucléotidique qui code pour une cytokine ou un fragment actif ou un variant de celle-ci.
  11. Vaccin selon la revendication 10, qui comprend un vecteur qui comprend une séquence nucléotidique qui code pour une cytokine ou un fragment actif ou un variant de celle-ci.
  12. Vaccin selon la revendication 10 ou la revendication 11, dans lequel la cytokine est une interleukine.
  13. Vaccin selon la revendication 10, dans lequel l'interleukine est choisie parmi l'IL-2 humaine ou l'IL-6 humaine.
  14. Composition pharmaceutique comprenant un vaccin tel que défini dans l'une quelconque des revendications précédentes et un véhicule ou un excipient acceptables sur le plan pharmaceutique.
  15. Vaccin multivalent comprenant un vaccin selon l'une quelconque des revendications 1 à 13 et un autre vaccin.
  16. Vecteur qui inclut une séquence qui code pour une forme atténuée du virus VEE telle que définie dans la revendication 1, destiné à être utilisé en tant que vaccin contre le VEE.
  17. Utilisation d'un vecteur comprenant une séquence qui code pour une forme atténuée du virus VEE telle que définie dans la revendication 1, pour la préparation d'un vaccin destiné à l'immunisation thérapeutique ou prophylactique contre le virus de l'encéphalite équine du Venezuela (VEE).
EP99920967A 1998-05-29 1999-05-05 Vaccin antiviral recombinant de l'encephalite equine du venezuela Expired - Lifetime EP1084261B8 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK99920967T DK1084261T3 (da) 1998-05-29 1999-05-05 Rekombinant vaccine mod venezuelansk hesteencephalitis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9811433 1998-05-29
GB9811433A GB2337755B (en) 1998-05-29 1998-05-29 Virus vaccine
PCT/GB1999/001387 WO1999063098A1 (fr) 1998-05-29 1999-05-05 Vaccin antiviral recombinant de l'encephalite equine du venezuela

Publications (3)

Publication Number Publication Date
EP1084261A1 EP1084261A1 (fr) 2001-03-21
EP1084261B1 true EP1084261B1 (fr) 2004-09-08
EP1084261B8 EP1084261B8 (fr) 2004-12-15

Family

ID=10832820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99920967A Expired - Lifetime EP1084261B8 (fr) 1998-05-29 1999-05-05 Vaccin antiviral recombinant de l'encephalite equine du venezuela

Country Status (14)

Country Link
US (2) US6936257B1 (fr)
EP (1) EP1084261B8 (fr)
AR (1) AR020080A1 (fr)
AT (1) ATE275631T1 (fr)
AU (1) AU3834999A (fr)
BR (1) BR9910814A (fr)
CA (1) CA2329133C (fr)
DE (1) DE69920011T2 (fr)
DK (1) DK1084261T3 (fr)
ES (1) ES2224655T3 (fr)
GB (1) GB2337755B (fr)
MX (1) MXPA00011708A (fr)
PT (1) PT1084261E (fr)
WO (1) WO1999063098A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
EP1418940A4 (fr) 2000-03-02 2006-09-20 Univ Emory Vecteurs d'expression d'adn et procedes d'utilisation
AU2002252199B2 (en) * 2001-03-08 2008-01-03 Emory University MVA expressing modified HIV envelope, GAG, and POL genes
DE602004000851T2 (de) * 2003-10-30 2007-05-16 Avago Technologies General Ip (Singapore) Pte. Ltd. Akustisch gekoppelter Dünnschicht-Transformator mit zwei piezoelektrischen Elementen, welche entgegengesetzte C-Axen Orientierung besitzten
RU2275937C1 (ru) * 2004-10-19 2006-05-10 Вирусологический центр НИИ Микробиологии Министерства обороны Российской Федерации Способ презентации вирусных антигенов иммунной системе хозяина, основанный на протеасомоопосредованной технологии, предназначенный для разработки методов биологической защиты
WO2008101349A1 (fr) * 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Vecteurs viraux recombinants pour la prévention et la protection contre une infection à alphavirus
EP2440251A4 (fr) * 2009-06-09 2013-01-16 Defyrus Inc Administration d'interféron pour une prophylaxie contre une infection pathogène ou un traitement d'une infection pathogène
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013151567A1 (fr) * 2012-04-04 2013-10-10 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research Institute Of Infectious Diseases Vaccins contre le virus de l'encéphalite équine et leurs procédés d'utilisation
SG11201407586WA (en) 2012-05-16 2014-12-30 Immune Design Corp Vaccines for hsv-2
PT3308641T (pt) * 2012-11-05 2019-10-24 Univ Yale Roedor imunodeficiente geneticamente modificado e métodos de utilização do mesmo.
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
CA2955015A1 (fr) 2014-07-15 2016-01-21 Immune Design Corp. Regimes de primo-vaccination/rappel avec un adjuvant d'agoniste tlr4 et un vecteur lentiviral
DK3407910T3 (da) 2016-01-29 2022-07-18 Bavarian Nordic As Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus
NZ787246A (en) 2016-04-15 2025-12-19 Alpine Immune Sciences Inc ICOS ligand variant immunomodulatory proteins and uses thereof
JP7527758B2 (ja) 2016-04-15 2024-08-05 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質およびその使用
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032120A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Proteines immunomodulatrices a variants de cd155 et leurs utilisations
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
KR20250083578A (ko) 2017-03-16 2025-06-10 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
ES2963638T3 (es) 2017-03-16 2024-04-01 Alpine Immune Sciences Inc Proteínas inmunomoduladoras de variantes de PD-L1 y usos de las mismas
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and their uses
EP3687561A4 (fr) 2017-09-01 2021-06-09 The Australian National University Molécules immunorégulatrices et leurs utilisations
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
IL273726B2 (en) 2017-10-18 2025-10-01 Alpine Immune Sciences Inc Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
EP3735417A1 (fr) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Protéines immunomodulatrices multi-domaine et leurs méthodes d'utilisation
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
KR20210089146A (ko) 2018-09-19 2021-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
US20220372106A1 (en) 2018-11-30 2022-11-24 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
MX2021012607A (es) 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
AU2021267276B2 (en) 2020-05-08 2024-10-24 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
WO2022236335A1 (fr) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Procédés de dosage et de traitement avec une protéine immunomodulatrice de fusion taci-fc
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
KR20250099778A (ko) 2022-10-04 2025-07-02 알파인 이뮨 사이언시즈, 인코포레이티드 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine

Also Published As

Publication number Publication date
GB9811433D0 (en) 1998-07-22
CA2329133C (fr) 2011-07-12
GB2337755A (en) 1999-12-01
BR9910814A (pt) 2001-02-13
GB2337755B (en) 2003-10-29
ATE275631T1 (de) 2004-09-15
EP1084261B8 (fr) 2004-12-15
CA2329133A1 (fr) 1999-12-09
USRE41745E1 (en) 2010-09-21
EP1084261A1 (fr) 2001-03-21
ES2224655T3 (es) 2005-03-01
US6936257B1 (en) 2005-08-30
PT1084261E (pt) 2005-01-31
AR020080A1 (es) 2002-04-10
AU3834999A (en) 1999-12-20
WO1999063098A1 (fr) 1999-12-09
DE69920011D1 (de) 2004-10-14
DK1084261T3 (da) 2005-01-17
DE69920011T2 (de) 2005-09-15
MXPA00011708A (es) 2005-10-13

Similar Documents

Publication Publication Date Title
EP1084261B1 (fr) Vaccin antiviral recombinant de l'encephalite equine du venezuela
JP7113924B2 (ja) 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン
KR100571479B1 (ko) Hiv에 대한 폴리엔브백신으로서 재조합 백시니아벡터의 혼합물
US11571471B2 (en) Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
KR100996330B1 (ko) Ｈｉｖ 조절/부속 단백질의 융합 단백질
EP1518932A1 (fr) Mutant du virus de la vaccine Ankara modifié (MVA) et utilisation correspondante
CN103189506A (zh) 包含痘苗病毒载体和仙台病毒载体的初免-加强疫苗用病毒载体
JP4719855B2 (ja) 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
Barefoot et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial
US5718902A (en) Double recombinant vaccinia virus vaccines
CA3179213A1 (fr) Vaccin contre le mers-cov
KR20230022206A (ko) 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신
JP2004526454A (ja) 組換えワクシニアウイルスベクター
JP2004529646A (ja) 病原性を低下させたウイルスベクター
Van der Ryst et al. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
BENNETT et al. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus
CA3009928C (fr) Vaccin contre le virus de l'encephalite equine base sur un virus modifie de la vaccine ankara (mva) recombinant
CN101020052A (zh) 基于复制型痘苗病毒载体的艾滋病疫苗
CZ127394A3 (en) Replication-capable recombinant virus, process of obtaining thereof and vaccine composition
KR20230156918A (ko) 재조합 vsv-sars-cov-2 백신

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20030703

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE SECRETARY OF STATE OF DEFENCE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BENNETT, ALICE MARIE

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB IE IT LI LU NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69920011

Country of ref document: DE

Date of ref document: 20041014

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Effective date: 20041207

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2224655

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050609

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: THE SECRETARY OF STATE FOR DEFENCE DSTL

Free format text: THE SECRETARY OF STATE FOR DEFENCE DSTL#PORTON DOWN#SALISBURY SP4 0JQ (GB) -TRANSFER TO- THE SECRETARY OF STATE FOR DEFENCE DSTL#PORTON DOWN#SALISBURY SP4 0JQ (GB)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20110603

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120523

Year of fee payment: 14

Ref country code: NL

Payment date: 20120531

Year of fee payment: 14

Ref country code: DK

Payment date: 20120521

Year of fee payment: 14

Ref country code: IE

Payment date: 20120522

Year of fee payment: 14

Ref country code: CH

Payment date: 20120523

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20120522

Year of fee payment: 14

Ref country code: FI

Payment date: 20120511

Year of fee payment: 14

Ref country code: BE

Payment date: 20120524

Year of fee payment: 14

Ref country code: FR

Payment date: 20120601

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120528

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20120504

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120511

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20130521

Year of fee payment: 15

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20131105

BERE Be: lapsed

Owner name: THE *SECRETARY OF STATE OF DEFENCE

Effective date: 20130531

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20131201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 275631

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131105

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130506

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20130531

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131201

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130505

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130505

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69920011

Country of ref document: DE

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140505

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130506

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130505